Classic preventive vaccines are designed to mimic the effectsof natural exposure to microbes. They provide a high level oflong-lasting protection against infection in the vast majorityof recipients and serve as free-standing preventive measures.Although a classic preventive vaccine remains the ultimate goalof efforts to develop a vaccine for protection against the humanimmunodeficiency virus (HIV), the enormous genetic diversityand other unique features of the HIV envelope protein have thusfar thwarted attempts to identify an effective candidate. However,we have learned from studies of HIV pathogenesis in humans andfrom animal models that a vaccine . . . [Full Text of this Article]
Obstacles to Vaccine Development
Early Focus on Monomeric Envelope Proteins
T-Cell Immunity in the Control of HIV Infection
T-Cell Vaccines
Complicating Factors
Research Issues
Conclusions
Source Information
From the Division of AIDS (M.I.J.) and the Office of the Director (A.S.F.), National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Address reprint requests to Dr. Fauci at the National Institute of Allergy and Infectious Diseases, 31 Center Dr., MSC 2520, Bldg. 31, Rm. 7A03, Bethesda, MD 20892, or at afauci@niaid.nih.gov.
This article has been cited by other articles:
Whitney, J. B., Luedemann, C., Hraber, P., Rao, S. S., Mascola, J. R., Nabel, G. J., Letvin, N. L.
(2009). T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen. J. Virol.
83: 10840-10843
[Abstract][Full Text]
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., Lehrman, J. K., Priddy, F. H., Olsen, O. A., Frey, S. M., Hammond, P. W., Protocol G Principal Investigators, , Kaminsky, S., Zamb, T., Moyle, M., Koff, W. C., Poignard, P., Burton, D. R.
(2009). Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science
326: 285-289
[Abstract][Full Text]
Bonsignori, M., Moody, M. A., Parks, R. J., Holl, T. M., Kelsoe, G., Hicks, C. B., Vandergrift, N., Tomaras, G. D., Haynes, B. F.
(2009). HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection. J. Immunol.
183: 2708-2717
[Abstract][Full Text]
Chen, H., Piechocka-Trocha, A., Miura, T., Brockman, M. A., Julg, B. D., Baker, B. M., Rothchild, A. C., Block, B. L., Schneidewind, A., Koibuchi, T., Pereyra, F., Allen, T. M., Walker, B. D.
(2009). Differential Neutralization of Human Immunodeficiency Virus (HIV) Replication in Autologous CD4 T Cells by HIV-Specific Cytotoxic T Lymphocytes. J. Virol.
83: 3138-3149
[Abstract][Full Text]
Wang, Y. E., Li, B., Carlson, J. M., Streeck, H., Gladden, A. D., Goodman, R., Schneidewind, A., Power, K. A., Toth, I., Frahm, N., Alter, G., Brander, C., Carrington, M., Walker, B. D., Altfeld, M., Heckerman, D., Allen, T. M.
(2009). Protective HLA Class I Alleles That Restrict Acute-Phase CD8+ T-Cell Responses Are Associated with Viral Escape Mutations Located in Highly Conserved Regions of Human Immunodeficiency Virus Type 1. J. Virol.
83: 1845-1855
[Abstract][Full Text]
Tomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C., Parks, R. J., Ashley, V. C., Lucas, J. T., Cohen, M., Eron, J., Hicks, C. B., Liao, H.-X., Self, S. G., Landucci, G., Forthal, D. N., Weinhold, K. J., Keele, B. F., Hahn, B. H., Greenberg, M. L., Morris, L., Karim, S. S. A., Blattner, W. A., Montefiori, D. C., Shaw, G. M., Perelson, A. S., Haynes, B. F.
(2008). Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. J. Virol.
82: 12449-12463
[Abstract][Full Text]
Perreau, M., Pantaleo, G., Kremer, E. J.
(2008). Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. JEM
205: 2717-2725
[Abstract][Full Text]
Yu, C. I., Gallegos, M., Marches, F., Zurawski, G., Ramilo, O., Garcia-Sastre, A., Banchereau, J., Palucka, A. K.
(2008). Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood
112: 3671-3678
[Abstract][Full Text]
Miura, T., Brockman, M. A., Brumme, C. J., Brumme, Z. L., Carlson, J. M., Pereyra, F., Trocha, A., Addo, M. M., Block, B. L., Rothchild, A. C., Baker, B. M., Flynn, T., Schneidewind, A., Li, B., Wang, Y. E., Heckerman, D., Allen, T. M., Walker, B. D.
(2008). Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes. J. Virol.
82: 8422-8430
[Abstract][Full Text]
Johnston, M. I., Fauci, A. S.
(2008). An HIV Vaccine -- Challenges and Prospects. NEJM
359: 888-890
[Full Text]
Gasper-Smith, N., Crossman, D. M., Whitesides, J. F., Mensali, N., Ottinger, J. S., Plonk, S. G., Moody, M. A., Ferrari, G., Weinhold, K. J., Miller, S. E., Reich, C. F. III, Qin, L., Self, S. G., Shaw, G. M., Denny, T. N., Jones, L. E., Pisetsky, D. S., Haynes, B. F.
(2008). Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design. J. Virol.
82: 7700-7710
[Abstract][Full Text]
Fauci, A. S., Johnston, M. I., Dieffenbach, C. W., Burton, D. R., Hammer, S. M., Hoxie, J. A., Martin, M., Overbaugh, J., Watkins, D. I., Mahmoud, A., Greene, W. C.
(2008). HIV Vaccine Research: The Way Forward. Science
321: 530-532
[Abstract][Full Text]
Astronomo, R. D., Lee, H.-K., Scanlan, C. N., Pantophlet, R., Huang, C.-Y., Wilson, I. A., Blixt, O., Dwek, R. A., Wong, C.-H., Burton, D. R.
(2008). A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. J. Virol.
82: 6359-6368
[Abstract][Full Text]
Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E., Hammer, S. M.
(2008). The Challenge of HIV-1 Subtype Diversity. NEJM
358: 1590-1602
[Full Text]
Balamurugan, A., Lewis, M. J., Kitchen, C. M. R., Robertson, M. N., Shiver, J. W., Daar, E. S., Pitt, J., Ali, A., Ng, H. L., Currier, J. S., Yang, O. O.
(2008). Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination. J. Virol.
82: 2784-2791
[Abstract][Full Text]
Harari, A., Bart, P.-A., Stohr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O., Barber, T., Moog, C., Liljestrom, P., Wagner, R., Wolf, H., Kraehenbuhl, J.-P., Esteban, M., Heeney, J., Frachette, M.-J., Tartaglia, J., McCormack, S., Babiker, A., Weber, J., Pantaleo, G.
(2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. JEM
205: 63-77
[Abstract][Full Text]
Steinbrook, R.
(2007). One Step Forward, Two Steps Back -- Will There Ever Be an AIDS Vaccine?. NEJM
357: 2653-2655
[Full Text]
Butler, N. S., Dandekar, A. A., Perlman, S.
(2007). Antiviral Antibodies Are Necessary To Prevent Cytotoxic T-Lymphocyte Escape in Mice Infected with a Coronavirus. J. Virol.
81: 13291-13298
[Abstract][Full Text]
Peut, V., Kent, S. J.
(2007). Utility of Human Immunodeficiency Virus Type 1 Envelope as a T-Cell Immunogen. J. Virol.
81: 13125-13134
[Abstract][Full Text]
Tonks, A.
(2007). Quest for the AIDS vaccine. BMJ
334: 1346-1348
[Full Text]